Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
94 results about "Treatment compliance" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment Compliance. Treatment compliance is defined as the degree to which patients’ behaviors (e.g., attending follow-up appointments, engaging in preventive care, following recommended medical regimens) correspond with the professional medical advice prescribed.
Patient treatment and monitoring systems and methods
ActiveUS20110105979A1Facilitating regulatory complianceMechanical/radiation/invasive therapiesMedical devicesMedical equipmentTherapeutic Devices
The invention provides apparatus and methods for home or other remote delivery of health care that gather subjective and objective measures of patient health and treatment, analyzing them (e.g., correlating them with one another and / or with norms) and reporting them to aid in on-going patient diagnosis and treatment (both on acute and chronic bases), as well as to aid physicians, nurses and other caregivers in decision support, monitoring treatment compliance, facilitating regulatory compliance, billing, and so forth. Thus, for example, in some aspects a health care delivery device comprising a medical treatment apparatus, such as a home hemodialysis or home peritoneal dialysis unit, that is coupled to a processor. The processor generates patient queries in connection with treatments rendered by the dialysis equipment (or other treatment apparatus). The queries are directed, at least in part, to subjective topics, such as the state of the patient's mental health and well being, quality of life, degrees of pain, views on success of therapy, and so forth. They are presented on an LCD screen or other output device coupled to the processor to elicit responses on a keyboard or other input device, also coupled to the processor.
Owner:FRESENIUS MEDICAL CARE HLDG INC
Inhaler module and related system
Apparatuses and methods for mounting an inhaler module to an inhaler, indicating compliance with a treatment regiment, shaking an inhaler and indicating mixing status, and reminding a user to prime the inhaler. The mounting element can have an elastic body adapted to interchangeably join both an inhaler and an inhaler module. Compliance can be indicated at a glance for a caregiver by providing an indication of the level of asthma medication treatment compliance. An accelerometer can be used to track mixing status of the medication canister and timestamped accelerometer data can be used to provide appropriate reminders to prime the inhaler.
Owner:SPECTRUM HEALTH INNOVATIONS
Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
InactiveUS20060253263A1Good curative effectMinimizing toxic side effectMicrobiological testing/measurementProteomicsMaintenance therapyAutoimmune condition
The present invention provides a method of effectively measuring risk for therapeutic toxicity of a subject having an autoimmune disorder or cancer and predicting and evaluating therapeutic efficacy of immunosuppressive therapies for autoimmune diseases and cancers before or after starting therapy. The present invention also provides for determining a drug metabolite level of a subject during therapy and measuring periodically the drug metabolite level of a subject on maintenance therapy to ensure treatment compliance and continued therapeutic response by measuring minimal clinical important differences (MCID) in the drug metabolite levels. The present invention also provides for a method to effectively optimize the selection and dose of immunosuppressive therapies of a subject having an autoimmune disease or cancer to improve therapeutic efficacy and reduce therapeutic toxicity prior to starting concomitant biologic therapy and before or after the subject has failed to respond to the at least one immunosuppressive agent.
Owner:MESHKIN BRIAN JAVAADE
Rapid establishment and/or termination of substantial steady-state drug delivery
ActiveUS20110076317A1Rapid terminationLarge deliveryPeptide/protein ingredientsMedical devicesDiseaseSide effect
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and / or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.
Owner:INTARCIA THERAPEUTICS INC
Patient treatment and monitoring systems and methods
ActiveUS8632485B2Facilitating regulatory complianceMechanical/radiation/invasive therapiesSolvent extractionLife qualityTreatment success
The invention provides apparatus and methods for home or other remote delivery of health care that gather subjective and objective measures of patient health and treatment, analyzing them (e.g., correlating them with one another and / or with norms) and reporting them to aid in on-going patient diagnosis and treatment (both on acute and chronic bases), as well as to aid physicians, nurses and other caregivers in decision support, monitoring treatment compliance, facilitating regulatory compliance, billing, and so forth. Thus, for example, in some aspects a health care delivery device comprising a medical treatment apparatus, such as a home hemodialysis or home peritoneal dialysis unit, that is coupled to a processor. The processor generates patient queries in connection with treatments rendered by the dialysis equipment (or other treatment apparatus). The queries are directed, at least in part, to subjective topics, such as the state of the patient's mental health and well being, quality of life, degrees of pain, views on success of therapy, and so forth. They are presented on an LCD screen or other output device coupled to the processor to elicit responses on a keyboard or other input device, also coupled to the processor.
Owner:FRESENIUS MEDICAL CARE HLDG INC
Oral respiration interface and a digital container
InactiveUS20100311003A1Decreased air pressure settingReduce airway resistanceOthrodonticsSnoring preventionOral appliancePoor adherence
The invention relates to oral appliances configured to maintain users upper airway unobstructed, facilitating improved breathing and elimination of snoring and obstructive sleep apnea. This invention covers mechanical and pneumatic means of maintaining users airway open. A smart container for appliances is also disclosed to be used in conjunction with any oral appliance as a system for wirelessly recording patient biofeedback, treatment compliance and live monitoring of the users medical condition.
Owner:KOZLOV ALEKSEY YURIY
System and method for measuring modifying and reporting treatment compliance
InactiveUS20060052844A1Efficiency benefitAdditional revenue opportunityElectrotherapyElectricityDocking station
One or more embodiments of the invention are directed to a system and method for measuring, modifying, and reporting treatment compliance. The system is configured to implement one or more treatment methods on a patient and is capable of performing one or more of the various functions described herein. In one embodiment of the invention the system comprises a device configured to administer one or more of the various forms of electrical stimulation (e.g., interferential stimulation, etc . . . ) and is typically coupled with a set of electrode or other mechanism that allows electrical current from the device to flow to the proper area of treatment on a patient. The device can also contain other components configured to collect vitals or whatever other information a physician or medical professional deems necessary to make treatment decisions. The device may take various forms and can, for instance, be a part of a larger machine or incorporated into a portable device the patient can readily move to different locations where treatment might be desired. In its portable form the device may have a docking station or other mechanism to recharge the unit.
Owner:NEWMAN TOM
Computer system and methods for constructing biological classifiers and uses thereof
The present invention provides systems and method for constructing classifiers that distinguish between trait subgroups using molecular marker data from blood samples. The invention further encompasses the use of the classifiers and combinations of molecular markers identified by the classifiers in a wide variety of applications including: diagnosis; prognosis; prediction of disease, stage of disease or disease risk; monitoring disease progression and / or regression; monitoring disease reoccurrence and identifying risk of disease reoccurrence; determining and / or predicting response to treatment and / or treatment outcomes; monitoring and / or predicting treatment compliance or non compliance and the like. The invention further provides a variety of selected molecular markers and a means to identify combinations of the selected molecular markers useful for diagnosing particular traits of interest.
Owner:GENENEWS
Rapid establishment and/or termination of substantial steady-state drug delivery
ActiveUS8298561B2Rapid terminationLarge deliveryPowder deliveryPeptide/protein ingredientsDiseaseSide effect
The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and / or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.
Owner:INTARCIA THERAPEUTICS INC
Pharmaceutical composition for treating cancer, comprising interferon alpha conjugate
ActiveUS20140219961A1Longer in vivo half-lifeHigh anticancer activityOrganic active ingredientsPeptide/protein ingredientsSide effectAnticarcinogen
A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
Owner:HANMI SCI CO LTD +1
Method and system for determining categories of sleep-related breathing events
ActiveCN104688239AMake sure it's correctImprove user experienceRespiratory organ evaluationSensorsTherapeutic effectChest respiratory movements
The invention discloses a method and a system for determining categories of sleep-related breathing events. The method includes acquiring chest breathing movement waveforms and abdominal breathing movement waveforms of patients; superimposing the chest breathing movement waveforms and the abdominal breathing movement waveforms to obtain superimposed waveforms; determining the categories of the sleep-related breathing events according to the superimposed waveforms when sleep-related breathing events of the patients occur. The method and the system for determining the categories of the sleep-related breathing events have the advantages that the superimposed waveforms of the chest breathing movement waveforms and the abdominal breathing movement waveforms of the patients are used as determination standards for determining the categories of the sleep-related breathing events, the determination standards are unaffected by air leakage of air channels, accordingly, the categories of the sleep-related breathing events can be accurately determined, accurate bases can be provided for regulating treatment pressures of positive-pressure ventilation treatment apparatuses, treatment effects and the treatment compliance can be greatly improved for the patients, and the use experience of the patients can be obviously improved.
Owner:BMC MEDICAL
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ActiveUS9889085B1Rapid terminationLarge deliveryPeptide/protein ingredientsDisease diagnosisDiseaseSide effect
The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and / or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.
Owner:INTARCIA THERAPEUTICS INC
System and method for patient self-assessment or treatment compliance
A system and method for transmission of alphanumeric messaging between mobile subscribers and an external system to send messages directly to the mobile subscriber's existing mobile phone to query them, for example, on the psychometric scale of interest. The resulting daily assessments may then be stored in a database that may be accessed via the interne to aid both the patient and a care provider in tracking the state and progress of the illness or symptoms which are being treated. It may allow the database to be queried to display trends over varying time intervals at any time in the past. The system and method may also provide for automatically notifying care providers if the patient is acutely having severe symptoms for a redefined duration and severity, and may facilitate a way to increase patient compliance with monitoring.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Arctigenin sublingual preparation
InactiveCN103446100AGuaranteed therapeutic effectFast blood flowOrganic active ingredientsAntineoplastic agentsDiseaseBiological availability
The invention claims protection for an arctigenin sublingual preparation and a use of the arctigenin sublingual preparation in the preparation of a medicine for treating a disease, and belongs to the field of medicines. According to the arctigenin sublingual preparation provided by the invention, a biological viscous material and an absorption promoter are added to effectively improve the absorption characteristic of the arctigenin sublingual preparation. When the arctigenin sublingual preparation provided by the invention is applied to treating a tumor, the tumor inhibition ratio of the medicine can be obviously improved, and the survival rate of a patient can be improved. The arctigenin sublingual preparation provided by the invention is high in biological availability, the treatment compliance of the patient can be improved, and therefore the arctigenin sublingual preparation has a good medical application prospect.
Owner:LUNAN PHARMA GROUP CORPORATION
Markers for screening anti-mycobacterial treatment efficacy
ActiveUS8580490B1Effectively resolving the diseaseBacterial antigen ingredientsMicrobiological testing/measurementAnti mycobacterialAntituberculous drugs
A method for metabolomically evaluating a subject's response to an anti-mycobacterial agent. The method includes the steps of generating multiple small molecule profiles using samples collected from the subject at or immediately prior to the start of treatment and at a times subsequent to the start of treatment with the anti-mycobacterial agent, identifying predetermined biomarkers in the small molecule profiles of the subject and comparing to a known standard established for the agent as an indication of whether the human is benefiting from treatment with the agent. Also provided are methods of monitoring treatment compliance, methods for establishing biomarkers indicative of treatment efficacy and validated biomarkers shown to be effective in assessing efficacy of anti-tuberculosis drugs.
Owner:COLORADO STATE UNIVERSITY
Mood state self-rating system based on electronized POMS self-rating scale
ActiveCN106166073AEffectively reflect changes in mood statesImprove time resolutionSensorsPsychotechnic devicesDiseaseSelf rating scale
The invention discloses a mood state self-rating system based on an electronized POMS self-rating scale. The system comprises a smart phone and a background cloud server. The independently developed electronized POMS self-rating scale is installed in the smart phone, scale data sent by the smart phone is received by the background cloud server, a mood state evaluating algorithm is operated, and an obtained main mood state and the change rule thereof, different mood state daily change rules of a user, total mood quantitative evaluation and other results are sent to the smart phone and fed back to the user. The electronized self-rating scale is operated through a sliding block, a button and other assemblies, the easy and convenient operation is suitable for daily mental state evaluation of mental patients and further consultation patients suffering from depression, mania, anxiety and the like, the treatment compliance of the patients is improved, mental state evaluation services can be provided for normal users in the environments of families and communities, and the accessibility of mental health medical treatment services is improved.
Owner:BEIJING UNIV OF TECH
Medical multifunctional orthodontic treatment appliance
InactiveCN107049530AComfortable to wearImprove treatment adherenceOthrodonticsSoft layerCurative effect
Owner:JILIN UNIV
Multi-cascade antihypertensive drug composition containing folic acid
InactiveCN106310278AGood antihypertensive effectEffective protectionOrganic active ingredientsCardiovascular disorderThiazide diureticTherapeutic effect
The invention relates to a drug composition. The drug composition consists of an effective treating amount of calcium antagonist (CCB), an angiotensin II receptor blocker (ARB), a thiazide diuretic, a folic acid compound and a pharmaceutically acceptable carrier, wherein the content of the CCB is 2-240 mg, the content of the ARB is 4-600 mg, the content of the thiazide diuretic is 0.625-25 mg, and the content of the folic acid compound is 0.4-0.4 mg. The drug composition has the advantages that the drug composition can effectively improve the treatment effect of reducing blood pressure of class-2 and class-3 hypertensive patients, strengthen the effect of protecting target organs of the patients and reduce the occurrence risk of cerebral apoplexy complications caused by high blood pressure. In addition, the drug composition can be conveniently taken by patients, the treatment compliance is greatly improved, and the medical costs can be also reduced.
Owner:SHENZHEN AUSA PHARM CO LTD +1
Compound aminoglycoside drug composition for local administration
InactiveCN107865966AReduce development costsEffective treatmentAntibacterial agentsOrganic active ingredientsScleritisNose
The invention provides a composition comprising an effective dose of etimicin or a pharmaceutically acceptable salt thereof, an anti-inflammatorily effective dose of steroids or non-steroid anti-inflammatory drugs, and an effective dose of a water-retaining or wetting agent or anti-xerophthalmia drug, and application of the composition to preparation of external drugs for local administration of the eyes, the nose or skin and for prevention and treatment of conjunctivitis in human beings or mammals, angular blepharitis, keratitis, scleritis, trachoma, xerophthalmia, cataract, otitis externa, otitis media, folliculitis, furuncle, pustule and the like. The composition provided by the invention has better curative effect or treatment compliance.
Owner:刘力
Smart goggle and smart goggle system
The embodiment of the invention discloses a smart goggle and a smart goggle system, through a monitoring device combined with the goggle and fixed together on a pair of glasses, is used for monitoring whether or not the goggle is effectively worn, and solves the technical problems of the overspread treatment compliance and the poor monitoring ability and the children amblyopia untimely subsequent diagnosis caused by the differences in social psychological factors, education degrees and economic capacities of parents and children in existing simple goggle overspread method, thus the timely and effective improvement of the vision is achieved, and the best treatment timing is prevented from being missed. The smart goggle system comprises a goggle covered on one side of the front glasses frame, and a monitoring device connected with the goggle and together with the goggle fixed on the glasses; the monitoring device is used for monitoring whether or not the goggle is effectively worn, and the smart goggle system further comprises a ranging module, a sensor, and a chip in communication connection with the ranging module and the sensor.
Owner:光朗(海南)生物科技有限责任公司
Fixing band for peritoneal dialysis catheter
InactiveCN108236754AProper fixationProperly protectiveCatheterPeritoneal dialysisLife qualityPeritoneal dialysis catheter
The invention relates to a fixing band for a peritoneal dialysis catheter. The fixing band comprises a long strip-shaped bellyband main body, wherein magic stickers are arranged at two ends of the bellyband main body for fixing the bellyband to the belly; hook surfaces of at least two catheter fixing rings are long strip-shaped magic stickers are fixedly arranged on the bellyband main body, and the hair sides of the magic stickers are vertical to the outer side of the bellyband main body; a short pipe fixing ring is used for fixing a short pipe at the tail end of the catheter; and an opening where a peritoneal dialysis catheter penetrates through is also formed in the bellyband main body. The catheter fixing ring can fix and protect the external catheter properly, the external catheter isprevented from sliding, and daily activity and sleep are not limited by positions, traction of an external pipe can be avoided, the life quality and the treatment compliance are improved, and peritoneal dialysis is smoothly carried out. Bleeding at a tunnel exit and an infection occurrence rate can be reduced, and the pain of patients and the economical burden are alleviated.
Owner:DALIAN UNIV
Method for treating cancer using an interferon alpha conjugate
ActiveUS9789202B2Longer in vivo half-lifeHigh anticancer activityOrganic active ingredientsPeptide/protein ingredientsSide effectCo administration
A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
Owner:HANMI SCI CO LTD +1
Dental treatment method combining tooth positioners and arch aligners
InactiveUS20180092713A1Additive manufacturing apparatusImpression capsClass iii malocclusionPatient compliance
A multiple-stage treatment method of orthodontically correcting teeth of a patient. The patient may wear, during the night and whenever convenient, a tooth positioner shaped to fit their dentition. The patient may then wear, at other times, an arch aligner shaped to fit their dentition. The patient may progress in stages, with the patient using a different arch aligner at every stage and a different tooth positioner every several stages. The combination of the arch aligner and tooth positioner may be used to treat, among other problems, class II and class III malocclusions, or transverse or vertical malocclusions, while maximizing the potential for patient compliance and reducing the number of tooth positioners and / or arch aligners that have to be made.
Owner:BOEHLAU EGGERT +1
Novel moxibustion therapy bed for Wei Huang moxibustion therapy and moxibustion therapy medicine formula
ActiveCN105496769AImprove treatment adherenceControl timeDevices for heating/cooling reflex pointsAntipyreticExternal applicationDual effect
The invention discloses a novel moxibustion therapy bed for Wei Huang moxibustion therapy and a moxibustion therapy medicine formula. The novel moxibustion therapy bed comprises a bed frame, an arch awning bracket, a reticular bed board, a moxibustion therapy box and a door plate, wherein the reticular bed board is arranged on the bed frame; the moxibustion therapy box is arranged below the reticular bed board; the door plate is arranged at one side of the moxibustion therapy box; and the arch awning bracket is arranged on the reticular bed board. Compared with the prior art, the novel moxibustion therapy bed disclosed by the invention inherits and carries forward a Wei Huang moxibustion therapy method, and gives play to dual effects of moxibustion and medicines, namely a self-made moxibustion therapy bin is used for applying moxibustion therapy oil outside moxibustion acupuncture points to perform moxibustion therapy, so that the moxibustion time and temperature can be better controlled, and the problems of uneven heating, scald and the like can be avoided. The Wei Huang moxibustion therapy method gives play to a penetration effect of the medicines, an acupuncture point stimulation effect and a warming effect of moxa leaves to the maximum extent, so to speak, the Wei Huang moxibustion therapy method greatly improves the curative effect of simple moxibustion or traditional Chinese medicine external application for treating rheumatoid arthritis, and reduces the occurrence of adverse reactions and increases the treatment compliance of patients at the same time.
Owner:兖矿新里程总医院
Combined formulation with improved stability
InactiveUS20140044784A1Reduce the amount requiredPrevent thrombosisBiocideAnimal repellantsAntithrombotic AgentSide effect
Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.
Owner:BORYUNG PHARMA CO LTD
Health-care medicated diet for large-intestine dampness-heat ulcerative colitis
InactiveCN106692784AHigh cure rateImprove efficiencyDigestive systemFood scienceSide effectLife quality
The invention discloses a health-care medicated diet for auxiliary prevention and treatment of large-intestine dampness-heat ulcerative colitis. The medicated diet is formed by two fixed combinations of a formula medicated diet and an intense humid type or intense heat type tea formula, wherein the fixed combinations use a formula A which consists of 20 parts of purslane herbs, 20 parts of lactuca indica, 20 parts of herba scutellariae barbatae, and 15 parts of sanguisorba, and a formula B which consists of 20 parts of raw pearl barley, 20 parts of radix codonopsis, 20 parts of glabrous greenbrier rhizomes, and 20 parts of Chinese yams. The intense heat type tea formula consists of 8 parts of honeysuckle flowers and 8 parts of chrysanthemums, and the intense humid type formula consists of 10 parts of flos gossampini and 8 parts of lotus leaves. Experiments prove that leading indicators of the cure rate, the total effective rate and the life quality of a group of people after eating the health-care medicated diet are apparently higher than those of a conventional group. Side effects and discomfortableness of people due to conventional medication, retention enema, and long-term oral administration of traditional Chinese medicines can be reduced, the treatment compliance is improved, and the health-care medicated diet is suitable for long-term maintenance treatment for the large-intestine dampness-heat ulcerative colitis. The materials of the medicated diet are convenient to take, and the health-care medicated diet is low in cost and convenient to use, has an exact auxiliary treatment effect and is free from side effects.
Owner:李婷珊
Clamping plate for treating hammer finger and method for fixing finger by clamping plate
The invention discloses a clamping plate for treating a hammer finger. The whole clamping plate is an arc-shaped plate body or bending-type plate body which is fixed on a finger back, a near side of the clamping plate is matched with the shape of the finger back of a middle-segment finger when the clamping plate is used for fixing, and a tail-segment finger is fixed on a far side arm of the clamping plate in a suspension way. According to the clamping plate disclosed by the invention, a good treatment effect can be effectively obtained for the tail-segment finger hyperextension of a patient, complications such as skin crushing can be reduced, the fixing operation is simple, the daily activities cannot be affected, and the treatment compliance of the patient is good.
Owner:廖立祥
Losartan potassium gastric floating capsule and preparation method thereof
ActiveCN103070848AImprove stabilityQuality improvementOrganic active ingredientsPharmaceutical delivery mechanismAlcoholRoom temperature
The invention relates to a losartan potassium gastric floating capsule, which comprises losartan potassium, PEG6000 (polyethyleneglycol), stearic acid, octodecyl alcohol, pre-gelatinized starch and mannite, wherein the losartan potassium is a powdery substance which is sieved with a 100-mesh sieve. A preparation method of the capsule comprises the following steps of: S1, mixing the PEG6000, the stearic acid and the octodecyl alcohol according to a certain proportion, heating to 64-66 DEG C, and smelting into a liquid; S2, heating the liquid mixture to 69-72 DEG C, and preserving heat for 9-11 minutes; S3, adding a proportional amount of losartan potassium into the mixture obtained in the step S2, keeping the temperature at 69-72 DEG C, and stirring uniformly; S4, adding a proportional amount of the pre-gelatinized starch and the mannite, and stirring uniformly; and S5, after the uniformity is qualified, filling in a hot state, covering a capsule cap, and cooling to the room temperature. The losartan potassium gastric floating capsule has the advantages that the medicament releasing time is long, the medicine taking times of a patient are reduced, the treatment compliance of the patient is enhanced, and the quality in a storage life is stable.
Owner:CHENGDU HENGRUI PHARMA
Peony seed oil self-emulsifying system composition and preparation method thereof
InactiveCN105708911AReduce dosageRaise the ratioMetabolism disorderDigestive systemSide effectHard Capsule
The invention provides a peony seed oil self-emulsifying system composition and a preparation method thereof. The self-emulsifying system composition comprises peony seed oil, an emulsifier and a co-emulsifier, further comprises a dispersing agent and / or a solid adsorbing agent and can be prepared into soft capsules, liquid capsules, hard capsules, granules and other oral dosage forms. After the self-emulsifying system composition enters the human body, self-micro-emulsification can be performed under the effect of gastrointestinal fluid, and absorption of the composition in the stomach and intestinal tracts can be promoted, so that the biological availability and effects of the peony seed oil self-emulsifying system composition are improved, side effects are small, and the treatment compliance of a patient for oral dosage medicine based on the peony seed oil self-emulsifying system composition can be improved.
Owner:GUANGZHOU OUHUA PHARMA
Straps-type portable multifunctional transfusion frame
The invention relates to a straps-type portable multifunctional transfusion frame, which comprises a backpack type wearing device, wherein a physiological spine curve device is arranged at the back ofthe backpack type wearing device corresponding to the position of a human spine; a telescopic rod device is mounted on the physiological spine curve device; the telescopic rod device comprises an outer rod C and an inner rod B; the lower end of the inner rod B is inserted into the outer rod C to realize expansion and contraction; the upper end of the inner rod B is connected with the bottom end of a telescopic arm device; a horizontal hanging rod is fixedly connected to the top end of the telescopic arm device; the telescopic arm device comprises a rod A; and the lower end of the rod A is connected with the upper end of the inner rod B through a rotating piece. The device solves the problem that the conventional transfusion frame is not easy to move or fix, so as to reduce the occurrenceof secondary injury to patients, and aims to solve the problem that patients suffer injury caused by non-therapeutic factors due to blood return, needle leakage, non-dripping of liquids and the like caused by inconvenient movement of the transfusion frame when patients go out or move in a large range clinically, so as to increase the satisfaction degree of the patients on treatment and to improvethe treatment compliance of the patients.
Owner:SHAANXI UNIV OF CHINESE MEDICINE +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com